NorthWest Biotherapeutics Inc (NWBO)

[seekinganswers]

"Nope, not in the L trial"
How could you possibly know that after "crossover" when the placebo group was eliminated?

First of all, the P III L trial is completely flawed and was a major failure.
Crossover spilled coffee all over any potential results, and was likely done on purpose because DCVax wasn't working.
PFS also failed and then they changed that endpoint as well. Then they went to OS and that also failed which led them to use external controls that didn't match the trial cohorts so as to further corrupt and jury rig the trial results. It's also noteworthy that the external controls were NOT in the original trial design. Bottom line, it was a failed AND corrupt trial in my opinion and the opinion of many scientists, medical doctors and researchers. Why do you think it has been over 2 years now and the MAA was sent to CHM because it had "major objections" and was "precluded from approval" by MHRA???
Grok also says TTF is a beneficial adjuvant to increase survival outcomes. You literally do not know anything of which you speak about.

The standard of care for glioblastoma multiforme (GBM) typically involves maximal safe surgical resection followed by concurrent radiation therapy and temozolomide chemotherapy, then adjuvant temozolomide. Survival outcomes vary based on factors like age, performance status, tumor molecular features (e.g., MGMT methylation), and extent of resection, but key benchmarks from clinical trials and real-world data are as follows:Median overall survival: Approximately 14.6–16 months.
2-year survival rate: Around 26–30%.
5-year survival rate: Approximately 5–10%, with the landmark EORTC-NCIC trial reporting 9.8% for patients receiving this treatment regimen.
These figures represent treated patients in controlled settings; real-world outcomes may be slightly lower overall due to comorbidities or incomplete treatment adherence. Add-on therapies like tumor-treating fields can improve rates further (e.g., up to 13% at 5 years in some trials), but the query focuses on the core standard of care.